Boehringer Ingelheim and Twist Bioscience team up to discover therapeutic antibodies September 9, 2021
Category: More news
Posted on Saturday, September 11, 2021 12:05 PM
– The research collaboration covers several research programs on antibodies –
SOUTH SAN FRANCISCO, CA, USA & INGELHEIM, Germany I September 09, 2021 I Twist Bioscience Corporation (NASDAQ: TWST), a company that enables customers to succeed with its high-quality synthetic DNA offering using its silicon platform, today announced an extensive research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.
âBoehringer Ingelheim believes that Twist’s ability to generate potent and diverse therapeutic antibodies by leveraging its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to provide groundbreaking opportunities for patients, âsaid Clive R. Wood, Ph .D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. âWe look forward to working with Twist on molecular targets in a wide range of disease areas,â added Wood.
Under the terms of the agreement, Twist Biopharma, a division of Twist, will use its “Library Library”, a panel of synthetic antibody display libraries derived only from sequences that exist in the human body, to identify candidate antibodies. potential therapies. Twist and Boehringer Ingelheim will work together to validate and optimize all of the resulting new antibody candidates, which could be sought in a range of therapeutic areas. Boehringer Ingelheim retains the exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered through the collaboration.
Twist will receive an upfront payment for each program registration. Additionally, Twist has the potential to earn up to a total of $ 710 million in clinical, regulatory and commercial milestone payments based on success for multiple target discovery programs.
âThis discovery collaboration with Boehringer Ingelheim covering many targets really illustrates the power of our antibody libraries. We have the ability to generate precise antibodies against a wide range of targets, which, together with Boehringer Ingelheim’s strength in drug development capabilities, could mean several new, more personalized treatments for patients in the future â, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.
About Twist Biopharma
By leveraging our unique ability to make DNA at scale, we can build proprietary antibody libraries designed precisely to match the sequences that occur in the human body. This library library provides our partners with a comprehensive and unbiased resource for therapeutic discovery and optimization of antibodies. This precise and rational approach to library fabrication, combined with sophisticated bioinformatics and software expertise, accelerates antibody discovery by lowering risk, increasing speed, and reducing failure rate of therapeutic antibody development.
About Twist Bioscience Corporation
Twist Bioscience is a leading and growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The heart of the platform is proprietary technology that develops a new method of making synthetic DNA by “writing” DNA onto a silicon chip. Twist takes advantage of its unique technology to manufacture a wide range of DNA-based synthetics, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for discovery and drug development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biological drug discovery. Twist manufactures products for many industries including healthcare, industrial chemicals, agriculture and academic research.
follow us on Twitter | Facebook | LinkedIn | Youtube
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas where unmet medical needs are great. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, human pharmacy, animal health and biopharmaceutical contract manufacturing.
Further information on Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.
THE SOURCE: Twist Biosciences